Detalles de la búsqueda
1.
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
J Gastroenterol Hepatol;
38(9): 1503-1509, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148148
2.
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
J Gastroenterol Hepatol;
36(11): 3041-3049, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34152636
3.
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.
Dig Dis Sci;
65(6): 1767-1776, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31722059
4.
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.
Dig Liver Dis;
56(1): 15-20, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37741749
5.
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Inflamm Bowel Dis;
29(2): 217-221, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35385102
6.
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease.
Dig Liver Dis;
54(5): 629-634, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34924320
7.
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
JGH Open;
5(3): 364-370, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33732883
8.
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Expert Opin Biol Ther;
20(11): 1381-1384, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32981373
9.
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Dig Liver Dis;
52(12): 1461-1466, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32601033
10.
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Drugs Aging;
37(5): 383-392, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32016824
11.
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
J Crohns Colitis;
13(2): 209-217, 2019 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30295785
12.
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Dig Liver Dis;
50(7): 675-681, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29576495
13.
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Dig Liver Dis;
50(12): 1292-1298, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30007516
Resultados
1 -
13
de 13
1
Próxima >
>>